How many investments has Quan Capital made?

Quan Capital has 28 tracked investments, 1 of which have exited via acquisition or IPO.

What stage does Quan Capital invest at?

Quan Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does Quan Capital focus on?

Quan Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Quan Capital located?

Quan Capital is headquartered in Shanghai, CN.

Who does Quan Capital co-invest with?

Quan Capital most often shares deals with New Enterprise Associates (NEA), Foresite Capital, LAV, among 43 tracked co-investors.

Quan Capital

Venture capital

Shanghai · Seed–Late Stage · 16 people tracked

Also known as QUAN CAPITAL MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Quan Capital positions itself as a company builder in the life sciences, working to identify, incubate and grow future industry leaders. The team describes itself as industry veterans focused on capturing evolving healthcare trends and emerging cutting-edge innovations. As a preferred partner, the firm emphasizes connecting portfolio companies with an extensive network and resources both globally and specifically in China, supporting biotech and therapeutics development.

Invests inBiotech Digital Health Healthtech Medical Devices China Europe Global Grand Cayman Shanghai United Kingdom United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Late Stage

Shanghai, CN

Instruments

Equity

Founded

2017

Private fund assets

$318M

VC funds

Tracked investments

Team · 16 people

from the firm's website & public directories

Samantha Du· Founding Managing Director· San Francisco, California, United Statesin

Dr. Samantha Du is Founding Managing Director of Quan Capital and the Founder, Chairperson, and CEO of Zai Lab, which she started in 2014 and took public on NASDAQ in 2017. She holds a Ph.D. in Biochemistry from the University of Cincinnati and worked at Pfizer, where she contributed to the development of products including two that gained FDA approval, before co-founding Hutchison MediPharma and Hutchison China MediTech (now HUTCHMED). She later joined Sequoia Capital China, where she led healthcare investments and served on public and private boards.

s•••@quancapital.comreveal

Marietta Wu· 董事总经理 (Managing Director)· China & USin

Dr. Marietta Wu is a Managing Director at Quan Capital, a life sciences venture fund with offices in China and the U.S. She co-founded Zai Lab, where she served as Chief Operating Officer, and previously was a Managing Director at BVCF (Boyle) responsible for its Greater China life sciences venture business. Earlier in her career she held strategy roles at Edwards Lifesciences and worked in finance and business development at Eli Lilly. She holds an MD from Shanghai Jiao Tong University School of Medicine, a PhD in medical science from a medical school in Ohio, and an MBA from the University of Michigan Ross School of Business.

m•••@quancapital.comreveal

Stella Xu· Managing Director· Zwolle, Overijssel, Netherlandsin

Stella Xu is Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US, focusing on cross-border value creation and global investments. Before joining Quan, she held R&D leadership roles at Roche, including VP/Site Head of Roche Innovation Center Shanghai, and earlier led healthcare management consulting engagements at McKinsey in the US. She holds a Ph.D. in Immunology from Northwestern University and a B.S. in Biophysics from Peking University.

s•••@quancapital.comreveal

Yingying Yang· Partner· Shanghaiin

Yingying Yang is a Partner at Quan Capital, based in the firm's Shanghai office, which she joined in 2017. She previously worked in Sanofi China's strategy planning group on pipeline prioritization and external licensing/M&A, and earlier as an associate consultant at L.E.K. Consulting covering healthcare and pharmaceuticals. She holds a Bachelor in Economics from Fudan University, an MSc in Finance from Imperial College London, and a dual Bachelor in Pharmacology from Shanghai Jiaotong University School of Medicine.

y•••@quancapital.comreveal

Harald Reinhart· Venture Partner

Dr. Harald Reinhart joined Quan Capital as a Venture Partner in 2025 and is CEO of Allphase Pharma Consulting LLC, as well as Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Before retiring in 2024, he led Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab, and previously held clinical development roles at Shionogi US, Novartis, and Bayer, working on approvals for compounds including ospemifene, Coartem, Famvir, Sebivo, and Cubicin. He holds a medical degree from the University of Würzburg and is board-certified in internal medicine and infectious diseases.

John Wong· Venture Partner

John Wong was a core member of Boston Consulting Group's Health Care practice and chairman of its Asia-Pacific region, and served on BCG's Global Executive and Operating committees. He focuses on the biopharmaceutical and medtech sectors, working with global pharmaceutical and medtech companies in Asia and local biopharmaceutical companies in China. Before joining BCG in 1982, he worked in R&D at Milliken Research, and he holds degrees from Imperial College London, MIT, and Harvard Business School.

Rick Xu· Venture Partner

Dr. Rick Xu is a Venture Partner at Quan Capital, which he joined in 2021, and has advised and acted as interim CMO for several of the firm's portfolio companies. He currently serves as Chief Medical Officer of Oricell Therapeutics and was previously the founding Chief Medical Officer of InnoCare Pharma (HKEX: 09969), with roughly 30 years in global clinical development at Roche/Genentech, Pfizer, and Sterling Winthrop. He earned his medical degree from Harbin Medical University, completed a Gastroenterology fellowship at Truman Medical Center, and holds a Ph.D. in Biopharmaceuticals from SUNY at Buffalo.

Angela Shen· Senior Advisor

Dr. Angela Shen is a Senior Advisor at Quan Capital and Vice President of Strategic Innovation Leaders at Mass General Brigham, where she works on translational medicine, clinical development, and regulatory affairs with a focus on gene and cell therapy. She previously served as Chief Medical Officer at biotech companies including Arcellx, NKarta, and Arvinas, acting CMO at Tizona, and held oncology drug development roles at Novartis, Exelixis, and Johnson & Johnson. At Novartis she led the clinical team behind the first multi-site registration CAR-T trial, resulting in the approval of Kymriah. She holds a BS from Rensselaer, an MD from Albany Medical College, and an MBA from NYU Stern.

Cherry Jin· Executive Assistant

Crystal Yin· Director, Finance

Lena Guo· Operation Manager

Peter Wirth· Senior Advisor

Peter Wirth has served as Chairman of the board of Syros Pharmaceuticals since 2017 and previously chaired FORMA Therapeutics Holdings LLC until its 2022 acquisition by Novo Nordisk, as well as serving as a director of Zai Lab Limited. He co-founded Lysosomal Therapeutics and held senior executive roles at Genzyme Corporation, including Executive Vice President of Legal and Corporate Development and Chief Risk Officer, and spent over 20 years as a partner and head of the biotechnology practice at Palmer & Dodge LLP. He holds a J.D. from Harvard Law School and a B.A. in Political Science from the University of Wisconsin at Madison.

Stacy Sun· Senior Accountant

Yiwei Gong· Senior Associate

Kui Wang· Senior Associate

k•••@quancapital.comreveal

Zhanghang Yan· Vice President· Shanghaiin

Zhanghang Yan is a Vice President at Quan Capital, working on investment idea generation and portfolio management. He previously spent four years as an associate at SDIC Venture Capital, focusing on biotech and IVD, and his work includes healthcare industry research, due diligence, and deal structuring. He holds a B.S. in Biology from Nanjing University and an M.S. in Genetics and Genomics from the University of California, Davis.

z•••@quancapital.comreveal

What they invest in

from 19 of 28 portfolio companies

Biotech ×18Healthtech ×13Digital Health ×3Deep Tech ×2Medical Devices ×2AI & Machine Learning ×1Hardware ×1

HQs:United States×8China×3

Investments · 28 tracked

founders shown can be your intro path

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in

Co-investorsForesite Capital OrbiMed Pontifax Venture Capital aMoon Novartis Venture Fund

NextCurenextcure.comNASDAQ: NXTC

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Pfizer Venture Investments Sofinnova Ventures +2 more

Zenas Biopharmazenasbio.com inNASDAQ: ZBIO

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)

BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsDelos Capital Longitude Capital New Enterprise Associates (NEA)Norwest Venture Partners SR One Capital Management Vivo Capital +1 more

Adcentrx Therapeuticsadcentrx.com inDec 2023

Adcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology.

BiotechHealthtech

Hui Li(Founder, President & CEO)in

Co-investorsEight Roads Ventures F-Prime Capital Delta Capital

Alebundalebund.com in

Alebund Pharmaceuticals develops innovative treatments for kidney diseases, with a pipeline covering chronic kidney conditions such as diabetic nephropathy, IgA nephropathy, FSGS, and ADPKD, as well as end-stage renal disease complications like hyperphosphatemia and anemia.

BiotechDigital HealthShanghai, CN

Co-investorsLAV Lilly Asia Ventures 3E Bioventures Capital Sherpa Healthcare Partners

Arcellxarcellx.com in

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)

BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in

Co-investorsLG Technology Ventures New Enterprise Associates (NEA)Samsara BioCapital Sixty Degree Capital Solasta Ventures SR One Capital Management +2 more

Armobioarmobio.com

Co-investorsAisling Capital LAV Lilly Asia Ventures

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed +3 more

Centrexion Therapeuticscentrexion.com in 𝕏

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.

BiotechHealthtechBaltimore, US

James N. Campbell(President, Chief Scientific Officer)Kerrie L. Brady(Executive Officer)Gregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)Smital Shah(Acting CBO)

Co-investorsCatalio Capital Management, LP EFung Capital New Enterprise Associates (NEA)

Crescendo Biologicscrescendobiologics.com in 𝕏Jul 2023 · $32M

Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699.

BiotechHealthtech

Co-investorsAndera Partners Astellas Venture Management LLC EMBL Ventures Future Planet Capital Sofinnova Partners Avlar BioVentures +1 more

Designtxdesigntx.com in

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical Devices

Co-investorsAvoro Capital Advisors WestRiver Group

Dmedglobaldmedglobal.com in 𝕏

Caidya is a global full-service clinical research organization (CRO) that supports biopharmaceutical companies with clinical trial design, execution, and patient recruitment across more than 40 countries.

BiotechDigital HealthHealthtech

Co-investorsQiming Venture Partners

Eluminexbioeluminexbio.com

Co-investorsCenova Capital 3E Bioventures Capital

iCarbonXicarbonx.com

Co-investorsThird Point Ventures

Kira Pharmaceuticalskirapharma.com in

Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology.

BiotechHealthtech

Wenru Song(Founder)

Co-investorsForesite Capital Vivo Capital Ikarian Capital

Medxtmcmedxtmc.com

Co-investorsQiming Venture Partners

OriCell

Developing a GPC3 CAR-T therapy for late-line advanced hepatocellular carcinoma.

Oricell Therapeuticsoricell.com in

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.

BiotechDeep TechHealthtechShanghai, CN

Helen Yang(Founder)in

Co-investorsQiming Venture Partners Vivo Capital

Pinnacle Medicinespinnaclemedicines.com in

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

Chengzao Sun(Founder)Sandeep Somani(Founder)

Co-investorsForesite Capital RA Capital

RareStone Grouprarestonegroup.com

Co-investorsVivo Capital

Sail Biomedicinessail.bio in 𝕏

Sail Biomedicines develops programmable RNA medicines using circular RNA technology (Endless RNA/eRNA) and targeted nanoparticles for delivery, applying generative AI to design therapies.

AI & Machine LearningBiotechDeep Tech

Co-investorsFlagship Pioneering Nextech Invest

Silexonsilexon.tech

Syrossyros.com

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

Co-investorsAisling Capital ARCH Venture Partners Flagship Ventures REDMILE

Tempest Therapeuticstempesttx.com

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.

BiotechHealthtechBrisbane, US

Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)

Co-investorsF-Prime Capital LAV Lilly Asia Ventures New Enterprise Associates (NEA)Roche Venture Fund

Therornatherorna.com

Therorna Inc. is a biotech company founded in 2021 that researches and develops circular RNA technology for innovative drugs and therapies, building a pipeline of preventive and therapeutic new drug candidates to address unmet clinical needs.

BiotechHealthtechBeijing, CN

Co-investorsCenova Capital

visit www.interiusbio.cominteriusbio.com

Co-investorsDC Investment Partners Longwood Fund Pfizer Venture Investments Agent Capital

Windward Biowindwardbio.com in

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMed RA Capital Sanofi Ventures SR One Capital Management Janus Henderson Investors Novo Holdings +3 more

Zidanmedicalzidanmedical.com in

Zidan Medical develops an endobronchial radiofrequency ablation system, using a small flexible RF catheter with "virtual electrode" forward-throw technology to deliver targeted, temperature-controlled energy to destroy lung lesions.

HardwareHealthtechMedical DevicesCupertino, US

Exits · 3

IPOs and acquisitions across the tracked portfolio

Adicet BioNASDAQ: ACETNextCureNASDAQ: NXTCZenas BiopharmaNASDAQ: ZBIO

Portfolio news

latest coverage across their companies

So, You Want to Join a Life Science Startup? A 2026 Resource Guide for Job Seekers | BioBuzz

Arcellx · biobuzz.io · Aug 14, 2026

RA Capital reports 9.99% stake in Adicet Bio | ACET SEC Filing - Form SCHEDULE 13G/A

Adicet Bio · stocktitan.net · Aug 14, 2026

Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates

Kira Pharmaceuticals · blockonomi.com · Aug 14, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Alebund · fiercebiotech.com · Aug 12, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Oricell Therapeutics · fiercebiotech.com · Aug 12, 2026

Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks.com

Tempest Therapeutics · tipranks.com · Jul 22, 2026

H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.com

NextCure · investing.com · Jul 15, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Avenzo · geekwire.com · Jul 13, 2026

Frequently asked questions

How many investments has Quan Capital made?: Quan Capital has 28 tracked investments, 1 of which have exited via acquisition or IPO.
What stage does Quan Capital invest at?: Quan Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Quan Capital focus on?: Quan Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Quan Capital located?: Quan Capital is headquartered in Shanghai, CN.
Who does Quan Capital co-invest with?: Quan Capital most often shares deals with New Enterprise Associates (NEA), Foresite Capital, LAV, among 43 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M